Medtronic (NYSE:MDT) reported earnings earlier this week, and the news was generally in-line with expectations (revenue slightly missed, off $10 million or $20 million from analyst expectations, depending on the source). At $4.6 billion, revenue was up 3% in constant currency, with $571 million coming from emerging markets, up 14% in constant currency. Medtronic guided for 3% to 5% revenue growth and 6% to 9% earnings growth in constant currencies.
With the litigation around CoreValve finished, Medtronic has some interesting opportunities ahead. In this video, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts David Williamson and Michael Douglass discuss the earnings and key takeaways for investors.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.